Loxo Oncology, Inc. (NASDAQ:LOXO) Director Keith T. Flaherty sold 7,250 shares of the business’s stock in a transaction dated Monday, August 21st. The stock was sold at an average price of $72.26, for a total value of $523,885.00. Following the sale, the director now owns 20,432 shares in the company, valued at approximately $1,476,416.32. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
Loxo Oncology, Inc. (NASDAQ LOXO) opened at 74.19 on Friday. The stock has a 50 day moving average price of $73.71 and a 200-day moving average price of $57.32. The firm’s market cap is $2.21 billion. Loxo Oncology, Inc. has a one year low of $17.14 and a one year high of $83.12.
Loxo Oncology (NASDAQ:LOXO) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.14) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.99) by $0.15. During the same quarter in the prior year, the company earned ($0.77) earnings per share. Analysts predict that Loxo Oncology, Inc. will post ($4.53) EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Loxo Oncology, Inc. (LOXO) Director Sells $523,885.00 in Stock” was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this report on another site, it was stolen and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://stocknewstimes.com/2017/08/26/loxo-oncology-inc-loxo-director-sells-523885-00-in-stock.html.
A number of large investors have recently modified their holdings of LOXO. Legal & General Group Plc raised its stake in shares of Loxo Oncology by 8.4% in the first quarter. Legal & General Group Plc now owns 3,682 shares of the biopharmaceutical company’s stock valued at $154,000 after buying an additional 284 shares during the period. Ameritas Investment Partners Inc. raised its stake in shares of Loxo Oncology by 31.3% in the second quarter. Ameritas Investment Partners Inc. now owns 1,758 shares of the biopharmaceutical company’s stock valued at $141,000 after buying an additional 419 shares during the period. Wells Fargo & Company MN raised its stake in shares of Loxo Oncology by 3.8% in the second quarter. Wells Fargo & Company MN now owns 16,095 shares of the biopharmaceutical company’s stock valued at $1,291,000 after buying an additional 592 shares during the period. Teachers Advisors LLC raised its stake in shares of Loxo Oncology by 4.3% in the fourth quarter. Teachers Advisors LLC now owns 22,139 shares of the biopharmaceutical company’s stock valued at $711,000 after buying an additional 905 shares during the period. Finally, Alps Advisors Inc. raised its stake in shares of Loxo Oncology by 7.4% in the second quarter. Alps Advisors Inc. now owns 23,601 shares of the biopharmaceutical company’s stock valued at $1,893,000 after buying an additional 1,623 shares during the period.
Several analysts have issued reports on the company. BidaskClub upgraded Loxo Oncology from a “sell” rating to a “hold” rating in a report on Saturday, August 12th. Zacks Investment Research downgraded Loxo Oncology from a “buy” rating to a “hold” rating in a report on Saturday, August 12th. Ifs Securities reiterated an “outperform” rating on shares of Loxo Oncology in a report on Tuesday, August 8th. Stifel Nicolaus reiterated a “buy” rating and issued a $94.00 target price (up previously from $71.00) on shares of Loxo Oncology in a report on Thursday, August 10th. Finally, BTIG Research reiterated a “buy” rating and issued a $75.00 target price on shares of Loxo Oncology in a report on Thursday, August 3rd. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $79.67.
Loxo Oncology Company Profile
Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.
Receive News & Ratings for Loxo Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
